Anti-Factor VII antibody [EP6185(2)]
- RabMAb
- Recombinant
- What is this?
Be the first to review this product! Submit a review
|
(1 Publication)
Rabbit Recombinant Monoclonal Factor VII antibody. Suitable for WB and reacts with Human samples. Cited in 1 publication.
View Alternative Names
Coagulation factor VII, Proconvertin, Serum prothrombin conversion accelerator, SPCA, F7
Related conjugates and formulations (1)
-
Anti-Factor VII antibody [EP6185(2)] - BSA and Azide free
Reactivity data
Product details
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
Factor 7a indirectly activates further components in the blood coagulation cascade. Upon activation factor 7a becomes a part of the tissue factor (TF) complex which includes tissue factor expressed on subendothelial cells. The complex triggers the activation of factor IX and factor X propagating the coagulation cascade downstream. This series of activations amplifies the signal for clot formation highlighting factor VII's integral role in initiating coagulation.
Pathways
Factor VII is primarily involved in the extrinsic pathway of the coagulation cascade. This pathway is initiated when factor 7a forms a complex with tissue factor a protein that becomes exposed at injury sites. Factor VII is also indirectly linked to the common coagulation pathway through activation of factor X. The interaction between these pathways ensures efficient and rapid clot formation. Additionally factor IX also interacts with factor VII in the intricate network of coagulation processes that sustain hemostasis.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (1)
Recent publications for all applications. Explore the full list and refine your search
F1000Research 12:172 PubMed38106655
2023
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com